Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 25;29(24):e202204004.
doi: 10.1002/chem.202204004. Epub 2023 Mar 20.

Broad-scope Syntheses of [11 C/18 F]Trifluoromethylarenes from Aryl(mesityl)iodonium Salts

Affiliations

Broad-scope Syntheses of [11 C/18 F]Trifluoromethylarenes from Aryl(mesityl)iodonium Salts

Sanjay Telu et al. Chemistry. .

Abstract

Efficient methods for labeling aryl trifluoromethyl groups to provide novel radiotracers for use in biomedical research with positron emission tomography (PET) are keenly sought. We report a broad-scope method for labeling trifluoromethylarenes with either carbon-11 (t1/2 =20.4 min) or fluorine-18 (t1/2 =109.8 min) from readily accessible aryl(mesityl)iodonium salts. In this method, the aryl(mesityl)iodonium salt is treated rapidly with no-carrier-added [11 C]CuCF3 or [18 F]CuCF3 . The mesityl group acts as a spectator allowing radiolabeled trifluoromethylarenes to be obtained with very high chemoselectivity. Radiochemical yields from aryl(mesityl)iodonium salts bearing either electron-donating or electron-withdrawing groups at meta- or para- position are good to excellent (67-96 %). Ortho-substituted and otherwise sterically hindered trifluoromethylarenes still give good yields (15-34 %). Substituted heteroaryl(mesityl)iodonium salts are also viable substrates. The broad scope of this method was further exemplified by labeling a previously inaccessible target, [11 C]p-trifluoromethylphenyl boronic acid, as a potentially useful labeling synthon. In addition, fluoxetine, leflunomide, and 3-trifluoromethyl-4-aminopyridine, as examples of small drug-like molecules and candidate PET radioligands, were successfully labeled in high yields (69-81 %).

Keywords: PET radiochemistry; carbon-11; diaryliodonium salts; fluorine-18; trifluoromethyl.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors declare no competing conflict of interest.

Figures

Figure 1.
Figure 1.
Examples of drugs and PET radiotracers containing an aryl trifluoromethyl group.
Figure 2.
Figure 2.
Effect of precursor amount and temperature on [11C]2a yield. See SI (Table S1) for corresponding[ time-course of [11C]3e yield.
Scheme 1.
Scheme 1.
Methods for bonding aryl carbon to radioactive trifluoromethyl groups.
Scheme 2.
Scheme 2.
Scope for the 11C-trifluoromethylation of meta- and para-substituted aryl substrates[a], [b], [c] [a] Reaction conditions: 1 (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (~ 0.5 mL). [11C]CF3H was added in DMF solution. [b] As for footnote [b] in Table 1 (n = 3). [c] The radio-HPLC yield of [11C]3e is in parentheses as mean ± SD for n = 3. [d] [11C]2n is the same product as [11C]3b produced from 1b (Table 1). [e] The triflate salt of the precursor was used. [f] Et3N•3HF was absent.
Scheme 3.
Scheme 3.
Scope for the 11C-trifluoromethylation of ortho-substituted aryl substrates[a], [b], [c] [a] Reaction conditions: 4 (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (~0.5 mL). [11C]CF3H was added in DMF solution. [b] As for footnote [b] in Table 1 (n = 3). [c] Radio-HPLC yield of [11C]3e in parenthesis as mean ± SD for n = 3. [d] [11C]5c is the same product as [11C]3a produced from 1a (Table 1). [e] Triflate salt of the precursor was used.
Scheme 4.
Scheme 4.
Scope for the 11C-trifluoromethylation of heteroaryl substrates[a], [b], [c] [a] Reaction conditions: 1c, or 6a–6e (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (0.5 mL); [11C]CF3H was added in DMF solution. [b] As for footnote [b] in Table 1 (n = 3). [c] Radio-HPLC yield of [11C]3e in parenthesis as mean ± SD for n = 3. [d] Iodonium salt 1c was used as precursor and the RCY in parenthesis is for [11C]2a as mean ± SD for n = 3. [e] The triflate salt of the precursor was used.
Scheme 5.
Scheme 5.
Synthesis of [11C]boronic acid synthons.[a],[b],[c] [a] Reaction conditions: 8 or 10 (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (~ 0.5 mL); [11C]Fluoroform was added as a DMF solution. [b] As for footnote [b] in Table 1. [c] Radio-HPLC yield of [11C]3e is in parenthesis as mean ± SD for n = 3.
Scheme 6.
Scheme 6.
11C-Labeling of known drugs and a PET radiotracer.[a],[b],[c] [a] Reaction conditions: 11 or 13 or 15 (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (~0.5 mL); [11C]CF3H was added in DMF solution. [b] Radio-HPLC yield shown in green as mean ± SD for n = 3. [c] Radio-HPLC yield of [11C]3e or [11C]3b in parentheses as mean ± SD for n = 3. [d] n = 2.
Scheme 7.
Scheme 7.
Scope for the 18F-trifluoromethylation of aryl substrates[a], [b], [c] [a] Reaction conditions: 4 (50 μmol), CuBr (5 μmol), KOtBu (15 μmol), Et3N•3HF (5 μmol), DMF (~0.5 mL). [18F]CHF3 was added as DMF solution. [b] As for footnote [b] in Table 1 (n = 2). [c] Radio-HPLC yield of [18F]3e in parentheses as mean ± SD for n = 2. [d] [18F]2n is the same product as [11C]3b produced from 1b (Table 1). [e] Triflate salt of the precursor was used. [f] Et3N•3HF was absent.

References

    1. Phelps ME, Proc. Natl. Acad. Sci. 2000, 97, 9226–9233; - PMC - PubMed
    2. Walker RC, Purnell GL, Jones-Jackson LB, Thomas KL, Brito JA, Ferris EJ, NeuroToxicology 2004, 25, 533–542; - PubMed
    3. Ametamey SM, Honer M, Schubiger PA, Chem. Rev. 2008, 108, 1501–1516. - PubMed
    1. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS, Nat. Rev. Drug. Discov. 2008, 7, 591–607; - PubMed
    2. Donnelly DJ, Sem. Nucl. Med. 2017, 47, 454–460; - PubMed
    3. Suridjan I, Comley RA, Rabiner EA, Brain Imaging Behav. 2019, 13, 354–365; - PubMed
    4. Donnelly DJ, Ch. 22, pp. 703–725, in Handbook of Radiopharmaceuticals, 2nd Ed., Kilbourn MR, Scott PJ (Eds), 2021. John Wiley & Sons Ltd.;
    5. Ghosh KK, Padmanabhan P, Yang C-T, Ng DCE, Palanivel M, Mishra S, Halldin C, Gulyás B Drug Discov. Today, 2022, 27, 280–291. - PubMed
    1. Pruis IJ, van Dongen GAMS, Veldhuijzen van Zanten SEM, Int. J. Mol. Sci. 2020, 21, 1029; - PMC - PubMed
    2. Unterrainer M, Eze, Ilhan H, Marschner S, Roengvoraphoj O, Schmidt-Hegemann NS, Walter F, Kunz WG, Munck af Rosenschöld P, Jeraj R, Albert NL, Grosu AL, Niyazi M, Bartenstein P, Belka C Radiat. Oncol. 2020, 15, 88. - PMC - PubMed
    1. https://www.xemed.com/markets/, Last accessed 4th March 2021.
    1. Yale HL, J. Med. Pharm. Chem. 1958, 1, 121–133; - PubMed
    2. Purser S, Moore PR, Swallow S, Gouverneur V, Chem. Soc. Rev. 2008, 37, 320–330; - PubMed
    3. Hagmann WK, J. Med. Chem. 2008, 51, 4359–4369; - PubMed
    4. Zhu W, Wang J, Wang S, Gu Z, Aceña JL, Izawa K, Liu H, Soloshonok VA, J. Fluorine Chem. 2014, 167, 37–54;
    5. Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA, J. Med. Chem. 2015, 58, 8315–8359; - PubMed
    6. Xu Z, Zhu Z, Peng C, Chen Z, Zhu W, Aisa HA, J. Chem. Inf. Model. 2020, 60, 6242–6250; - PubMed
    7. Francis F, Wuest F, Molecules 2021, 26, 6478. - PMC - PubMed

MeSH terms

LinkOut - more resources